[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[3] |
HUANG Jinjian, ZHANG Xiaomeng, ZHANG Bing, DING Xueli, YANG Ying, LIN Zhijian.
Cardiovascular risk signaling mining and mechanism of uric acid-lowering drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 866-871.
|
[4] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[5] |
HE Xiong, MA Junlong, YANG Guoping.
Adverse events caused by HER2 conjugated antibodies via FAERS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.
|
[6] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[7] |
CHEN Xiao, GUO Xiaojing, XU Jinfang, WEI Lianhui, CHEN Chenxin, LIANG Jizhou, ZHENG Yi, YE Xiaofei.
Machine learning method in the detection of adverse drug reaction signals of brigatinib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 639-645.
|
[8] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|
[9] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[10] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[11] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[12] |
ZHANG Xuanyi, KONG Wenqiang, ZHONG Hong, DENG Huiyuan, SHU Yunfeng.
Signal mining of adverse drug events of abiraterone based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1148-1153.
|
[13] |
REN Yuqin, LI Xin, YU Min, SU Yuwen.
Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
|
[14] |
ZHANG Chi.
Data mining of adverse drug events of alirocumab from openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
|
[15] |
CHEN Tianyu, CHEN Qiying, ZHANG Yuezhen.
Adverse reactions of solriamfetol after listing based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 432-435.
|